Kasper Hansen

Associate Professor, Neuroscience

Contact Information

Division Of Biological Sciences
(406) 243-4820
Personal Website:

Office Address

Division Of Biological Sciences
ISB 216
32 Campus Dr MS 1552
Missoula MT, 59812

After completing a B.Sc. in Chemistry and a M.Sc. in Molecular Biology at University of Aarhus in Denmark, Kasper Hansen received his Ph.D. in Molecular Pharmacology from University of Copenhagen, Denmark in 2006. Following a postdoctoral fellowship in the Department of Pharmacology, Emory University School of Medicine, he moved to the University of Montana in 2013. Kasper Hansen is a faculty in the Division of Biological Sciences, the Center for Biomolecular Structure and Dynamics (CBSD), and the Center for Structural and Functional Neuroscience (CSFN).

More information on the research program and publications can also be found here: Kasper Hansen lab.

Research Interests

Heterotetrameric NMDA-type ionotropic glutamate receptorWhen glutamate is released from the presynaptic membrane during fast excitatory neurotransmission, it readily diffuses across the synaptic cleft and activates ligand-gated ion channels present at the postsynaptic membrane. These ionotropic glutamate receptors have been divided into three classes based on agonist pharmacology and structure, namely AMPA, kainate, and NMDA receptors. NMDA receptors are critically involved in many important neuronal functions, including frequency encoding of information, synaptic plasticity, and neuronal development. However, NMDA receptors also play overt roles in a variety of neurological and psychiatric disorders in the central nervous system, including depression, schizophrenia, ischemia, seizures, traumatic brain injury, Parkinson’s, Huntington’s, and Alzheimer’s diseases. For these reasons, there has been widespread interest in understanding structure, function, and regulation of NMDA receptors for the purpose of developing new treatments for a number of diseases. The overarching goal of research in the laboratory is to enhance the synthetic pharmacology of NMDA receptors (i.e. to develop novel agonists, antagonists, and modulators), and to identify and validate new strategies and targets that can be exploited for therapeutic intervention. The laboratory uses a multidisciplinary approach (electrophysiology, synthetic biology, molecular screening, biochemistry, structural biology, and molecular modeling) to advance our understanding of the relationships between structure, function, and pharmacology of NMDA receptors. These efforts are mainly been divided into four areas:

Pharmacology and function of triheteromeric NMDA receptors

There are seven NMDA receptor subunits (GluN1, GluN2A-D, and GluN3A-B) that assemble as tetrameric receptors. Recombinant studies almost exclusively describe diheteromeric receptors assembled from GluN1 and one type of GluN2, but at least three different subunits have been identified in most, if not all, NMDA receptor-expressing cells, and the majority of native receptors are triheteromers in that they contain three different subunits. These triheteromeric NMDA receptors are poorly understood due to the problem that co-expression of three different subunits in heterologous expression systems will yield multiple different receptor populations. We recently developed a method to tightly control the subunit composition of NMDA receptors, thereby enabling selective expression of triheteromeric NMDA receptors. This new approach provides opportunities to develop therapeutic agents that target the disease-relevant native triheteromeric NMDA receptors and to study properties relevant to synaptic signaling.

For examples of studies on triheteromeric NMDA receptors, see:

Structure and function of GluN3-containing NMDA receptors

Many basic questions related to the structure, function, and pharmacology of GluN3-containing NMDA receptors are unanswered. Despite the lack of basic understanding, we know from studies using GluN3-deficient and GluN3-overexpressing mice that GluN3 subunits are involved in synapse maturation, synaptic plasticity, and neuroprotection. They could therefore be promising new therapeutic targets in several neurological diseases that include excitotoxicity or cognitive impairment.

For examples see:

Development of novel subunit-selective NMDA receptor ligands

For examples see:

Mechanism and structural determinants of NMDA receptor modulators

For examples see:



See full publication list in PubMed and citation records in ResearchGate or Google Scholar.

More information on the research program and publications can be found here: Kasper Hansen lab.

Kasper Hansen

Search Again